<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238433</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000248</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-HEM-04083-L</secondary_id>
    <secondary_id>OHSU-IRB-248</secondary_id>
    <nct_id>NCT00238433</nct_id>
  </id_info>
  <brief_title>Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous
      blood-forming cells (stem cells) in the blood and bone marrow. Giving the patient their
      healthy stem cells will help their bone marrow make new stem cells that become red blood
      cells, white blood cells, and platelets.

      PURPOSE: This phase II trial is studying how well busulfan, melphalan, and thiotepa work in
      treating patients who are undergoing an autologous stem cell transplant for Hodgkin's or
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the therapeutic efficacy of a myeloablative preparative regimen comprising
           busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell
           (PBSC) transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

        -  Determine the toxic effects of this preparative regimen in these patients.

      OUTLINE:

        -  Myeloablative preparative regimen: Patients receive busulfan IV over 3 hours on days -8
           to -6, melphalan IV over 15-30 minutes on days -5 and -4, and thiotepa IV over 2 hours
           on days -3 and -2.

        -  Peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation
           on day 0 followed by filgrastim (G-CSF) IV over 30 minutes beginning on day 5 and
           continuing until blood counts recover.

        -  Intrathecal chemotherapy: Patients with a history of treated Central Nervous System
           (CNS) disease or at high-risk for CNS relapse receive methotrexate and cytarabine
           intrathecally (IT) for 2 doses each within 10 days prior to transplantation and 4-6
           doses each beginning on day 32 post-transplantation.

        -  Consolidation therapy: Patients with residual bulk disease at 80-100 days
           post-transplantation that is &gt; 2.5 cm by CT scan may undergo local radiotherapy to
           residual scar/disease provided it can be encompassed in a single radiation port and the
           volume of lung to be irradiated is â‰¤ 20%.

      After completion of study treatment, patients are followed weekly for 1 month, monthly for 6
      months, every 3 months for 6 months, every 6 months for 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>3, 6, 9, 12, 18, and 24 months post transplantation</time_frame>
    <description>The data presented below represents the total number of subjects (out of 36) that reached disease-free survival status during Months 3, 6, 9, 12, 18, and 24 time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapy-Related Toxicities</measure>
    <time_frame>Through 24 months post transplantation</time_frame>
    <description>The table presented below reflects how many participants (out of 36 total) presented an adverse event related to the treatment regimen within each toxicity category. To review specific adverse events, both related and unrelated to study treatment, please refer to Adverse Events Section.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine: filgrastim
5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) &gt; 1500 for 2 consecutive days.
Drug: busulfan
3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Drug: melphalan
50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Drug: thiotepa
250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support
The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
Procedure/Surgery: peripheral blood stem cell transplantation
Performed 36-48 hours following last chemotherapy dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC&gt; 1500 for 2 consecutive days.</description>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.</description>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.</description>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>250 mg/m2/day/iv on days -3 and -2</description>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <description>The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.</description>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Performed 36-48 hours following last chemotherapy dose.</description>
    <arm_group_label>Filgrastim/Melphalan/Thiotepa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Intermediate- or high-grade non-Hodgkin's lymphoma (NHL), meeting 1 of the
                  following criteria:

                    -  In first complete remission (CR) AND at high-risk for relapse, as defined by
                       all of the following criteria:

                         -  High age-adjusted International Prognostic Index category AND meets the
                            following criteria at diagnosis:

                              -  Stage III or IV disease

                              -  Lactic dehydrogenase abnormal

                              -  Eastern Cooperative Oncology Group (ECOG) score 0-2

                         -  Mantle cell histology

                    -  Primary refractory disease

                    -  Beyond first CR

               -  Low-grade NHL

                    -  Beyond second relapse

               -  Hodgkin's lymphoma

                    -  Primary refractory disease OR beyond first CR

          -  Must have an adequate number of stored autologous peripheral blood stem cells (PBSCs)
             (i.e., 2.0 x 10^6 hematopoietic progenitor cell antigen (CD34)-positive cells/kg)

               -  Patients who are not able to mobilize a sufficient number of PBSCs may use bone
                  marrow instead

          -  No active CNS disease NOTE: A new classification scheme for adult non-Hodgkin's
             lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot;
             lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade
             lymphoma. However, this protocol uses the former terminology.

        PATIENT CHARACTERISTICS:

        Age

          -  0 to 70

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin &lt; 2 times upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 times ULN

        Renal

          -  Creatinine â‰¤ 2.0 mg/dL

          -  Creatinine clearance â‰¥ 50 mL/min

        Pulmonary

          -  No significant pulmonary dysfunction, defined as Diffusing Capacity the Lung for
             Carbon monoxide (DLCO) &lt; 60% of predicted

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for â‰¥ 2 months before and during
             study participation

          -  HIV negative

          -  No significant active infection that would preclude PBSC transplantation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior transplantation

          -  No other concurrent blood products during PBSC transplantation

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  More than 60 days since prior local or regional radiotherapy

        Surgery

          -  Not specified

        Other

          -  More than 30 days since prior investigational drugs

          -  No concurrent amphotericin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Maziarz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <disposition_first_submitted>November 28, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 28, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 29, 2016</disposition_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Richard Maziarz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage III childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Busulfan/Melphalan/Thiotepa</title>
          <description>Treatment:
Drug: Busulfan 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Drug: Melphalan 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Drug: Thiotepa 250 mg/m2/day/iv on days -3 and -2.
Procedure/Surgery: Peripheral blood stem cell transplantation. Performed 36-48 hours following last chemotherapy dose.
The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
Administration Growth Factor: Filgrastim 5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) &gt; 1500 for 2 consecutive days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Busulfan/Melphalan/Thiotepa</title>
          <description>Treatment Plan:
Drug: Busulfan 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Drug: Melphalan 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Drug: Thiotepa 250 mg/m2/day/iv on days -3 and -2.
Procedure/Surgery: Peripheral blood stem cell transplantation. Performed 36-48 hours following last chemotherapy dose.
The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
Administration Growth Factor: Filgrastim 5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC&gt; 1500 for 2 consecutive days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-Free Survival</title>
        <description>The data presented below represents the total number of subjects (out of 36) that reached disease-free survival status during Months 3, 6, 9, 12, 18, and 24 time points.</description>
        <time_frame>3, 6, 9, 12, 18, and 24 months post transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan/Melphalan/Thiotepa</title>
            <description>Busulfan: 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Melphalan: 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Thiotepa: 250 mg/m2/day/iv on days -3 and -2
Procedure/Surgery: bone marrow ablation with stem cell support
The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
Procedure/Surgery: Peripheral blood stem cell transplantation. Performed 36-48 hours following last chemotherapy dose.
Growth factor administration: Filgrastim 5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC&gt; 1500 for 2 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival</title>
          <description>The data presented below represents the total number of subjects (out of 36) that reached disease-free survival status during Months 3, 6, 9, 12, 18, and 24 time points.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapy-Related Toxicities</title>
        <description>The table presented below reflects how many participants (out of 36 total) presented an adverse event related to the treatment regimen within each toxicity category. To review specific adverse events, both related and unrelated to study treatment, please refer to Adverse Events Section.</description>
        <time_frame>Through 24 months post transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan/Melphalan/Thiotepa</title>
            <description>Treatment Plan:
Drug: Busulfan 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Drug: Melphalan 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Drug: Thiotepa 250 mg/m2/day/iv on days -3 and -2.
Procedure/Surgery: Peripheral blood stem cell transplantation. Performed 36-48 hours following last chemotherapy dose.
The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
Administration Growth Factor: Filgrastim 5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC&gt; 1500 for 2 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapy-Related Toxicities</title>
          <description>The table presented below reflects how many participants (out of 36 total) presented an adverse event related to the treatment regimen within each toxicity category. To review specific adverse events, both related and unrelated to study treatment, please refer to Adverse Events Section.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dermatological Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Toxicites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For all adverse events grade 3 or higher is recorded for the first 100 days post transplant. After 100 days post transplant, all unexpected grade 3 and 4 adverse events will be recorded and reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BuMelTT</title>
          <description>*For all adverse events grade 3 or higher is recorded for the first 100 days post transplant. After 100 days post transplant, all unexpected grade 3 and 4 adverse events will be recorded and reported.
TREATMENT PLAN:
Busulfan: 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Melphalan: 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Thiotepa: 250 mg/m2/day/iv on days -3 and -2
Procedure/Surgery: bone marrow ablation with stem cell support
The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
Procedure/Surgery: Peripheral blood stem cell transplantation. Performed 36-48 hours following last chemotherapy dose.
Growth factor administration: Filgrastim</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ileum obstruction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Influenza A</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Opioid overdose</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Distended abdomen</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Auto GVHD</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis (C. diff)</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Entercolitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pancolitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal ALT (alanine aminotransferase ) lab result</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abnormal amylase lab result</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness (lower limb)</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis/early bronchopneumonia</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>General skin rash</sub_title>
                <description>Unrelated to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Thiotepa-induced skin rash</sub_title>
                <description>Related to treatment regimen.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Maziarz, MD</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-6365</phone>
      <email>maziarzr@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

